Upcoming & Enrolling Adult Cystic Fibrosis Clinical Trials
The studies listed below will soon be or are currently enrolling participants. Our list of upcoming studies is constantly evolving. Please contact our research team to learn about studies in our pipeline that may not be listed here!
To learn more about upcoming clinical trials in CF, visit the Cystic Fibrosis Foundation’s Clinical Trials Finder.
Last updated January 9, 2026.
This is an accordion element with a series of buttons that open and close related content panels.
The AIRTIVITY™ Study | A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
“This study will test the effectiveness, safety, and tolerability of BI 1291583, a drug intended to reduce inflammation in the lungs.” – CFF Trial Finder Profile
Principal Investigator: Andrew Braun, MD, MHS
Lead Research Coordinator: Megan Devereaux
Key Inclusion Criteria:
– Clinical history of bronchiectasis
– 18 years and older
– History of pulmonary exacerbations requiring antibiotic treatment within the last year
Time Commitment: Alternating in-person and phone visits over the course of 52 weeks up to 76 weeks.
See CFF Trial Finder profile here.
See ClinicalTrials.gov profile here.
STOP360-IP-22 | Antibiotic Treatment of Pulmonary Exacerbations
“This study will look at pulmonary exacerbations, which are a worsening of respiratory symptoms, in people with CF who need to be treated with intravenous (IV) antibiotics. It will compare treatment with one antibiotic (a beta-lactam) to treatment with two antibiotics (tobramycin and a beta-lactam) to learn whether there is a difference in lung function and symptom improvement between the two groups.” – CFF Trial Finder Profile
Principal Investigator: Andrew Braun, MD, MHS
Lead Research Coordinator: Nikki Cole
Key Inclusion Criteria:
– 6 Years and Older
– Positive Pseudomonas aeruginosa culture in last two years
Time Commitment: 3 study visits over 48 days.
See CFF Trial Finder profile here.
See ClinicalTrials.gov profile here.
VX21-522-001 | Inhaled mRNA Therapy
“This study will evaluate the safety and tolerability of VX-522, an investigational inhaled messenger RNA (mRNA), in adults with CF whose mutations are not responsive to CFTR modulator therapy.” – CFF Trial Finder Profile
Principal Investigator: Andrew Braun, MD, MHS
Lead Research Coordinator: Nikki Cole
See CFF Trial Finder profile here.
See ClinicalTrials.gov profile here.
REACH-OB-23 | Observational study for people not taking CFTR modulators
“The REACH observational study will collect health information on people with CF 12 years and older who do not take CFTR modulators.” – CFF Trial Finder Profile
Principal Investigator: Hara Levy, MD MMSc
Lead Research Coordinator: Nikki Cole
See CFF Trial Finder profile here.
See ClinicalTrials.gov profile here.
Ongoing Adult Cystic Fibrosis Clinical Trials
The clinical trials listed below are currently ongoing and are no longer accepting new participants. Our studies are both investigational and observational. We enjoy working with families from all around the Midwest. Please contact our research team to learn about clinical trials in our pipeline that may not be listed here!
Last updated January 9, 2026.
This is an accordion element with a series of buttons that open and close related content panels.
VX20-121-104 | Open Label Once a Day Modulator
“The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in participants with cystic fibrosis.” – ClinicalTrials.gov Profile
Principal Investigator: Andrew Braun, MD
Lead Research Coordinators: Megan Devereaux
See ClinicalTrials.gov profile here.